The proportion of CTNNB1-mutant samples (5/23, 21.7%) in incident cancers was similar to the proportion of CTNNB1-mutant tumors detected in prevalent cancers [51] (10/48, 20.8%; p = 1.0, Figure 3A,B). This evidence concerns the gene CTNNB1 and cancer.